Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Rhea-AI Summary
Ardelyx (Nasdaq: ARDX) will report full year and fourth quarter 2025 results and host a conference call on Thursday, February 19, 2026 at 4:30 p.m. Eastern Time. The call will feature the executive leadership team and include a business update.
Live audio will be webcast via the Investors section at the company's website and archived for replay for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ARDX
In the Feb 5 session, ARDX declined 5.15%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Patent issuance | Positive | -0.6% | USPTO issued new tenapanor formulation patent expiring November 26, 2042. |
| Jan 28 | Phase 3 trial start | Positive | -0.4% | First patient dosed in ACCEL Phase 3 CIC study of IBSRELA (tenapanor). |
| Jan 08 | Prelim 2025 revenue | Positive | +20.1% | Preliminary 2025 revenue, strong IBSRELA growth and 2026 guidance outlined. |
| Nov 07 | Real-world data | Positive | +1.1% | Real-world XPHOZAH data showed phosphate reductions and patient satisfaction. |
| Nov 05 | Conference participation | Positive | +6.3% | Management participation in Jefferies Global Healthcare Conference fireside chat. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive milestones have often seen mixed price reactions, with strong gains on revenue/guidance news but occasional small declines on positive patent and clinical updates.
In the last few months, Ardelyx reported several meaningful developments before scheduling its February 19, 2026 earnings call. A January update outlined preliminary 2025 product revenue of about $378 million, strong growth for IBSRELA and XPHOZAH, and detailed 2026 revenue guidance, which coincided with a 20.07% gain. Earlier, the company initiated the Phase 3 ACCEL trial in chronic idiopathic constipation and secured a new U.S. patent for tenapanor formulations, both followed by modest share declines. Real-world XPHOZAH data and a Jefferies conference appearance produced smaller positive moves, showing a mixed but generally constructive reaction pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura Williams M.D., M.P.H., Chief Patient Officer and Interim Chief Medical Officer.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
